Synergistic Antibacterial Effect between Silibinin and Antibiotics in Oral Bacteria by Lee, Young-Soo et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 618081, 7 pages
doi:10.1155/2012/618081
Research Article
SynergisticAntibacterial EffectbetweenSilibininand Antibiotics
in OralBacteria
Young-Soo Lee,1 Kyeung-Ae Jang,2 andJeong-Dan Cha2
1Department of Dental Hygiene, Sun Moon University, Asan-si 336-708, Republic of Korea
2Department of Dental Hygiene, College of Natural Sciences, Dongeui University, Busan 614-714, Republic of Korea
Correspondence should be addressed to Jeong-Dan Cha, joungdan@deu.ac.kr
Received 7 May 2011; Revised 4 July 2011; Accepted 14 July 2011
Academic Editor: Ikhlas A. Khan
Copyright © 2012 Young-Soo Lee et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Silibinin is a composition of the silymarin group as a hepatoprotective agent, and it exhibits various biological activities, including
antibacterial activity. In this study, the antibacterial activities of silibinin were investigated in combination with two antimicrobial
agents against oral bacteria. Silibinin was determined with MIC and MBC values ranging from 0.1 to 3.2 and 0.2 to 6.4µg/mL,
ampicillin from 0.125 to 64 and 0.5 to 64µg/mL, gentamicin from 2 to 256 and 4 to 512µg/mL, respectively. The ranges of MIC50
and MIC90 were 0.025–0.8µg/mL and 0.1–3.2µg/mL, respectively. The antibacterial activities of silibinin against oral bacteria
were assessed using the checkerboard and time-kill methods to evaluate the synergistic eﬀects of treatment with ampicillin or
gentamicin. The results were evaluated showing that the combination eﬀects of silibinin with antibiotics were synergistic (FIC
index < 0.5) against all tested oral bacteria. Furthermore, a time-kill study showed that the growth of the tested bacteria was
completely attenuated after 2–6h of treatment with the MBC of silibinin, regardless of whether it was administered alone or with
ampicillin or gentamicin. These results suggest that silibinin combined with other antibiotics may be microbiologically beneﬁcial
and not antagonistic.
1.Introduction
Dental plaque is a ﬁlm of microorganisms on the tooth
surface that plays an important role in the development of
caries and periodontal diseases [1–3]. Corrective treatment
for such infectious diseases requires the reduction and/or
elimination of bacterial accumulations in the retentive sites
on the top of the teeth (occlusal surfaces) and between
teeth by daily toothbrushing and frequent dental cleanings
or prophylaxis [4, 5]. Several antibacterial agents including
ﬂuorides,phenolderivatives,ampicillin,erythromycin,peni-
cillin, tetracycline, and vancomycin have been used widely
in dentistry to inhibit bacterial growth [6–8]. However,
excessive use of these chemicals can result in derangements
of the oral and intestinal ﬂora and cause side eﬀects such as
microorganism susceptibility, vomiting, diarrhea, and tooth
staining [9–11]. These problems necessitate further search
for natural antibacterial agents that are safe for humans and
speciﬁc for oral pathogens. Natural products have recently
been investigated more thoroughly as promising agents to
prevent oral diseases, especially plaque-related diseases such
as dental caries [12–15].
Silymarin is a standardized extract obtained from the
seeds of milk thistle (Silybum marianum), which contains
approximately 70–80% of the silymarin ﬂavonolignans [16–
18]. Silibinin is a major bioactive component of silymarin
ﬂavonolignans [19, 20]. Both silymarin and silibinin have
been used as traditional drugs for ≥2000 years to treat a
range of liver disorders, including hepatitis and cirrhosis,
and to protect the liver against poisoning from exposure to
chemical and environmental toxins, including insect stings,
mushroom poisoning, and alcohol [16, 20, 21]. Recently, in
vitroand in vivo studies have reported thatsilibinin possesses
antioxidant, anti-inﬂammatory, and antiarthritic activities,
and it has chemopreventive eﬃcacy on lung carcinoma,
prostate cancer, breast carcinoma, hepatic disorder, and
colon carcinoma [22–25]. In a previous study, silibinin
showed antibacterial activity against the Gram-positive bac-
teria Bacillus subtilis and Staphylococcus epidermidis [26].2 Journal of Biomedicine and Biotechnology
In this study, we investigated the synergistic antibacterial
activity of silibinin in combination with the existing antimi-
crobial agents against oral bacteria.
2.MaterialsandMethods
2.1. Bacterial Strains. The oral bacterial strains used in this
study were Streptococcus mutans ATCC 25175, Streptococcus
sanguinis ATCC 10556, Streptococcus sobrinus ATCC 27607,
Streptococcus ratti KCTC (Korean collection for type cul-
tures) 3294, Streptococcus criceti KCTC 3292, Streptococ-
cus anginosus ATCC 31412, Streptococcus gordonii ATCC
10558, Actinobacillus actinomycetemcomitans ATCC 43717,
Fusobacterium nucleatum ATCC 10953, Prevotella intermedia
ATCC 25611, and Porphyromonas gingivalis ATCC 33277.
Brain-heart infusion broth supplemented with 1% yeast
extract (Difco Laboratories, Detroit, Mich) was used for all
bacterial strains except P. intermedia and P. gingivalis. For
P. intermedia and P. gingivalis, brain-heart infusion broth
containing hemin and menadione was used.
2.2. Minimum Inhibitory Concentrations/Minimum Bac-
tericidal Concentrations Assay. The minimum inhibitory
concentrations (MICs) were determined for silibinin by
the broth dilution method [15] and were carried out in
triplicate. The antibacterial activities were examined after
incubation at 37◦C for 18h (facultative anaerobic bacteria),
24h (microaerophilic bacteria), and 1-2 days (obligate
anaerobic bacteria) under anaerobic conditions. MICs were
determined as the lowest concentration of test samples
that resulted in a complete inhibition of visible growth
in the broth. Following anaerobic incubation of MICs
plates, the minimum bactericidal concentrations (MBCs)
were determined on the basis of the lowest concentration of
silibinin that kills 99.9% of the test bacteria by plating out
onto each appropriate agar plate. Ampicillin and gentamicin
were used as standard antibiotics in order to compare the
sensitivity of silibinin against test bacteria.
2.3. Checker-Board Dilution Test. The antibacterial eﬀects
of a combination of silibinin, which exhibited the highest
antimicrobial activity, and antibiotics were assessed by
the checkerboard test as previously described [15]. The
antimicrobial combinations assayed included silibinin with
ampicillin or gentamicin. Serial dilutions of two diﬀerent
antimicrobial agents were mixed in cation-supplemented
Mueller-Hinton broth. After 24h of incubation at 37◦C, the
MIC was determined to be the minimal concentration at
which there was no visible growth. The fractional inhibitory
concentration index (FICI) is the sum of the FICs of each
of the drugs, which in turn is deﬁned as the MIC of each
drug when it is used in combination divided by the MIC of
the drug when it is used alone. The interaction was deﬁned
as synergistic if the FIC index was less than or equal to 0.5,
additive if the FIC index was greater than 0.5 and less than
or equal to 1.0, indiﬀerent if the FIC index was greater than
1.0 and less than or equal to 2.0, and antagonistic if the FIC
index was greater than 2.0.
2.4. Time-Kill Curves. Bactericidal activities of the drugs
under study were also evaluated using time-kill curves
on oral bacteria. Tubes containing Mueller-Hinton supple-
mented to which antibiotics had been added at concentra-
tions of the MIC50 were inoculated with a suspension of the
test strain, giving a ﬁnal bacterial count 5∼6 × 106 CFU/mL.
The tubes were thereafter incubated at 37◦C in an anaerobic
chamber, and viable counts were performed at 0, 0.5, 1,
2, 3, 4, 5, 6, 12, and 24h after addition of antimicrobial
agents, on agar plates incubated for up to 48h in anaerobic
chamber at 37◦C. Antibiotic carryover was minimized by
washings by centrifugation and serial 10-fold dilution in
sterile phosphate-buﬀered saline, pH 7.3. Colony counts
were performed in duplicate, and means were taken. The
solid media usedforcolonycountswere brain-heart infusion
(BHI) agar for streptococci and brain-heart infusion agar
containing hemin and menadione for P. intermedia and P.
gingivalis.
3. Results and Discussion
The antibacterial activities and synergistic eﬀects of silibinin
alone or with antibiotics were evaluated in oral bacteria. The
antibacterial activities of the ATCC and KCTC strains of oral
bacteria to silibinin, ampicillin, and gentamicin alone and in
combination are presented in Table 1.T h eM I C s / M B C sf o r
silibinin were found to be either 0.1/0.2 or 3.2/6.4µg/mL, for
ampicillin either 0.125/0.5 or 64/64µg/mL, and for gentam-
icin,either2/4or256/512µg/mL.SilibininMIC50 andMIC90
values for oral cariogenic bacteria were 0.025–0.2µg/mL and
0.1–0.8µg/mL, respectively, while for periodontopathogenic
bacteria these values were 0.1–0.4µg/mL and 0.4–3.2µg/mL,
respectively (Table 1).
In combination with silibinin, the MIC for ampicillin
was reduced to ≥4–8-fold in all tested bacteria, producing
a synergistic eﬀect as deﬁned by FICI ≤ 0.5. The MBC
for ampicillin has shown synergistic eﬀects in all tested
bacteria expect S. sanguinis, S. ratti,a n dP. intermedia
(Table 2). In combination with silibinin, the MIC/MBC for
gentamicin was reduced to ≥4–8-fold in all tested bacteria
expect S. sanguinis and S. ratti by FICI ≥ 0.75 (Table 3).
Many articles have revealed that Gram-positive bacteria
was more sensitive to plant antimicrobials than Gram-
negative bacteria, suggesting that the results are due to the
diﬀerence between the presence and absence of the outer
membrane which can limit drug diﬀusion in harmony with
multidrug transporters [15, 27–29]. In this study, silibinin
also shows susceptibility on Gram-positive bacteria as well
as Gram-negative bacteria. Many attempts have been made
to eliminate S. mutans from the oral ﬂora [30]. Antibiotics
such as ampicillin, chlorhexidine, erythromycin, penicillin,
tetracycline, and vancomycin have been very eﬀective in
preventing dental caries [6, 31, 32]. Moreover, the antifungal
activities have shown that neither silibinin nor silymarin
II had antifungal activity against yeast [30]. The Gram-
positive bacteria-speciﬁc properties of silibinin are causedJournal of Biomedicine and Biotechnology 3
Table 1: Antibacterial activity of silibinin and antibiotics in oral bacteria.
Samples Silibinin (µg/mL) Ampicillin Gentamicin
MIC50< MIC90< MIC/MBC MIC/MBC (µg/mL)
S. mutans ATCC 251751 0.05 0.2 0.2/0.4 0.125/0.5 8/16
S. sanguinis ATCC 10556 0.1 0.4 0.4/0.4 0.5/1 64/64
S. sobrinus ATCC 27607 0.1 0.4 0.4/0.8 0.5/1 4/8
S. ratti KCTC 32942 0.2 0.8 0.8/0.8 0.5/1 16/32
S. criceti KCTC 3292 0.2 0.8 0.8/1.6 1/2 8/16
S. anginosus ATCC 31412 0.1 0.8 0.8/1.6 1/2 32/32
S. gordonii ATCC 10558 0.025 0.1 0.1/0.2 0.5/1 32/32
A. actinomycetemcomitans ATCC 43717 0.4 1.6 1.6/3.2 64/64 4/8
F. nucleatum ATCC 51190 0.4 3.2 3.2/6.4 2/4 2/4
P. intermedia ATCC 49049 0.4 1.6 1.6/3.2 4/8 16/32
P. gingivalis ATCC 33277 0.1 0.4 0.4/0.8 0.5/1 256/512
1American Type Culture Collection (ATCC).
2Korean collection for type cultures (KCTC).
Table 2: Synergistic eﬀects of the silibinin with ampicillin against oral bacteria.
Strains Agent MIC/MBC (µg/mL) FIC FICI2 Outcome
Alone Combination1
S. mutans ATCC 251753 Silibinin 0.2/0.4 0.05/0.1 0.25/0.25 0.5/0.5 Synergistic/synergistic
Ampicillin 0.125/0.5 0.0312/0.125 0.25/0.25
S. sanguinis ATCC 10556 Silibinin 0.4/0.4 0.1/0.2 0.25/0.5 0.5/0.75 Synergistic/additive
Ampicillin 0.5/1 0.125/0.25 0.25/0.25
S. sobrinus ATCC 27607 Silibinin 0.4/0.8 0.1/0.2 0.25/0.25 0.5/0.5 Synergistic/synergistic
Ampicillin 0.5/1 0.125/0.25 0.25/0.25
S. ratti KCTC 32944 Silibinin 0.8/0.8 0.1/0.2 0.125/0.25 0.375/0.75 Synergistic/additive
Ampicillin 0.5/1 0.125/0.5 0.25/0.5
S. criceti KCTC 3292 Silibinin 0.8/1.6 0.2/0.4 0.25/0.25 0.5/0.375 Synergistic/synergistic
Ampicillin 1/2 0.25/0.25 0.25/0.125
S. anginosus ATCC 31412 Silibinin 0.8/1.6 0.2/0.4 0.25/0.25 0.5/0.5 Synergistic/synergistic
Ampicillin 1/2 0.25/0.5 0.25/0.25
S. gordonii ATCC 10558 Silibinin 0.1/0.2 0.025/0.05 0.25/0.25 0.5/0.5 Synergistic/synergistic
Ampicillin 0.5/1 0.125/0.25 0.25/0.25
A. actinomycetemcomitans ATCC 43717 Silibinin 1.6/3.2 0.2/0.8 0.125/0.25 0.25/0.5 Synergistic/synergistic
Ampicillin 64/64 8/16 0.125/0.25
F. nucleatum ATCC 51190 Silibinin 3.2/6.4 0.4/1.6 0.125/0.25 0.375/0.5 Synergistic/synergistic
Ampicillin 2/4 0.5/1 0.25/0.25
P. intermedia ATCC 49049 Silibinin 1.6/3.2 0.2/0.8 0.125/0.25 0.375/0.75 Synergistic/additive
Ampicillin 4/8 1/4 0.25/0.5
P. gingivalis ATCC 33277 Silibinin 0.4/0.8 0.1/0.2 0.25/0.25 0.5/0.5 Synergistic/synergistic
Ampicillin 0.5/1 0.125/0.25 0.25/0.25
1The MIC and MBC of the silibinin with ampicillin.
2The fractional inhibitory concentration index (FIC index).
3American Type Culture Collection (ATCC).
4Korean collection for type cultures (KCTC).4 Journal of Biomedicine and Biotechnology
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Figure 1: Time-kill curves of MIC of silibinin alone and its combination with MIC50 of ampicillin or gentamicin against S. mutans, S.
sanguinis, S. sobrinus, S. anginosus, S. criceti,a n dS. ratti. Bacteria were incubated with silibinin (•), silibinin + ampicillin (◦), and silibinin
+ gentamicin () over time. Data points are the mean values ± S.E.M. of six experiments. CFU: colony-forming units.Journal of Biomedicine and Biotechnology 5
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Table 3: Synergistic eﬀects of the silibinin with gentamicin against oral bacteria.
Strains Agent MIC/MBC (µg/mL) FIC FICI2 Outcome
Alone Combination1
S. mutans ATCC 251753 Silibinin 0.2/0.4 0.05/0.1 0.25/0.25 0.5/0.5 Synergistic/synergistic
Gentamicin 8/16 2/4 0.25/0.25
S. sanguinis ATCC 10556 Silibinin 0.4/0.4 0.1/0.2 0.25/0.5 0.375/0.75 Synergistic/additive
Gentamicin 64/64 8/16 0.125/0.25
S. sobrinus ATCC 27607 Silibinin 0.4/0.8 0.05/0.2 0.125/0.25 0.375/0.5 Synergistic/synergistic
Gentamicin 4/8 1/2 0.25/0.25
S. ratti KCTC 32944 Silibinin 0.8/0.8 0.2/0.4 0.25/0.5 0.5/0.625 Synergistic/additive
Gentamicin 16/32 4/4 0.25/0.125
S. criceti KCTC 3292 Silibinin 0.8/1.6 0.2/0.4 0.25/0.25 0.375/0.375 Synergistic/synergistic
Gentamicin 8/16 1/2 0.125/0.125
S. anginosus ATCC 31412 Silibinin 0.8/1.6 0.2/0.2 0.25/0.125 0.375/0.375 Synergistic/synergistic
Gentamicin 32/32 4/8 0.125/0.25
S. gordonii ATCC 10558 Silibinin 0.1/0.2 0.025/0.05 0.25/0.25 0.375/0.5 Synergistic/synergistic
Gentamicin 32/32 4/8 0.125/0.25
A. actinomycetemcomitans ATCC 43717 Silibinin 1.6/3.2 0.4/0.8 0.25/0.25 0.5/0.5 Synergistic/synergistic
Gentamicin 4/8 1/2 0.25/0.25
F. nucleatum ATCC 51190 Silibinin 3.2/6.4 0.8/1.6 0.25/0.25 0.5/0.5 Synergistic/synergistic
Gentamicin 2/4 0.5/1 0.25/0.25
P. intermedia ATCC 25611 Silibinin 1.6/3.2 0.4/0.8 0.25/0.25 0.5/0.375 Synergistic/synergistic
Gentamicin 16/32 4/4 0.25/0.125
P. gingivalis ATCC 33277 Silibinin 0.8/0.8 0.1/0.2 0.125/0.25 0.375/0.375 Synergistic/synergistic
Gentamicin 256/512 64/64 0.25/0.125
1The MIC and MBC of the silibinin with gentamicin.
2The fractional inhibitory concentration index (FIC index).
3American Type Culture Collection (ATCC).
4Korean collection for type cultures (KCTC).
by the inhibition of RNA and protein synthesis rather than
by attacking the bacterial membrane [25, 26]. The bacterial
eﬀect of silibinin with ampicillin or gentamicin against oral
bacteria was conﬁrmed by time-kill curve experiments. The
silibinin (MIC or MIC50) alone resulted in a rate of killing
increasing or not changing in CFU/mL at time-dependent
manner,withamorerapidrateofkillingbysilibinin(MIC50)
with ampicillin (MIC50) or gentamicin (MIC50) (Figures
1 and 2) .As t r o n gb a c t e r i c i d a le ﬀect was exerted in drug
combinations.
4. Conclusion
These ﬁndings suggest that silibinin fulﬁlls the conditions
required of a novel cariogenic bacteria and periodontal
pathogens, particularly bacteroides species, drug and may be
useful in the future in the treatment of oral bacteria.
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